Recent studies have highlighted the increase in treatment resistant depression. Of particular concern is the rising trend of depression and suicide rates among Young Adults. Ketamine was approved for treatment resistant depression in 2019 by the US Food and Drug Administration. It received an additional indication for treatment of suicidality. While intranasal Ketamine is approved for depression, recent data about intravenous infusion of Ketamine in controlled inpatient settings has been promising. ECT has a long-standing trend for being used for resistant depression and recent comparison trials have revealed positive results when head-to-head comparisons are made with Ketamine. Future studies need to focus on patient selection and wherein treatment algorithm should Ketamine be selected as treatment modality.
References
[1]
Lochmann, D. and Richardson, T. (2018) Selective Serotonin Reuptake Inhibitors. M. InMacaluso, & S. Preskorn (Eds.), Antidepressants, Springer International Publishing, 135-144. https://doi.org/10.1007/164_2018_172
[2]
Gaynes, B.N., Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Spencer, D. and Fava, M. (2008) The STAR*D Study: Treating Depression in the Real World. Cleveland Clinic Journal of Medicine, 75, 57-66. https://doi.org/10.3949/ccjm.75.1.57
[3]
Goodwin, R.D., Dierker, L.C., Wu, M., Galea, S., Hoven, C.W. and Weinberger, A.H. (2022) Trends in U.S. Depression Prevalence from 2015 to 2020: The Widening Treatment Gap. American Journal of Preventive Medicine, 63, 726-733. https://doi.org/10.1016/j.amepre.2022.05.014
[4]
McIntyre, R.S., Rosenblat, J.D., Nemeroff, C.B., Sanacora, G., Murrough, J.W., Berk, M., et al. (2021) Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. American Journal of Psychiatry, 178, 383-399. https://doi.org/10.1176/appi.ajp.2020.20081251
[5]
Xiong, J., Lipsitz, O., Chen-Li, D., Rosenblat, J.D., Rodrigues, N.B., Carvalho, I., et al. (2021) The Acute Antisuicidal Effects of Single-Dose Intravenous Ketamine and Intranasal Esketamine in Individuals with Major Depression and Bipolar Disorders: A Systematic Review and Meta-Analysis. Journal of Psychiatric Research, 134, 57-68. https://doi.org/10.1016/j.jpsychires.2020.12.038
[6]
Griffiths, C., O’Neill-Kerr, A., De-Vai, R., Sore, T. and Silva, K.D. (2019) Ketamine Infusion (KI) in Treatment Resistant Depression (TRD): Retrospective Clinical Data Analysis. Open Journal of Depression, 8, 59-70. https://doi.org/10.4236/ojd.2019.83007
[7]
Brody, B.D., Park, N., Christian, A., Shaffer, C.W., Smetana, R., Kotbi, N., et al. (2024) Ketamine for Major Depressive Disorder during an Inpatient Psychiatric Admission: Effectiveness, Adverse Events, and Lessons Learned. Journal of Affective Disorders, 351, 293-298. https://doi.org/10.1016/j.jad.2024.01.207
[8]
Anand, A., Mathew, S.J., Sanacora, G., Murrough, J.W., Goes, F.S., Altinay, M., et al. (2023) Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal of Medicine, 388, 2315-2325. https://doi.org/10.1056/nejmoa2302399
[9]
Ibrahim, L., Diazgranados, N., Luckenbaugh, D.A., Machado-Vieira, R., Baumann, J., Mallinger, A.G., et al. (2011) Rapid Decrease in Depressive Symptoms with an N-Methyl-D-Aspartate Antagonist in ECT-Resistant Major Depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35, 1155-1159. https://doi.org/10.1016/j.pnpbp.2011.03.019
[10]
Acevedo-Diaz, E.E., Cavanaugh, G.W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C.A., et al. (2020) Comprehensive Assessment of Side Effects Associated with a Single Dose of Ketamine in Treatment-Resistant Depression. Journal of Affective Disorders, 263, 568-575. https://doi.org/10.1016/j.jad.2019.11.028
[11]
Agarkar, S., Hurt, S., Lisanby, S. and Young, R.C. (2012) ECT Use in Unipolar and Bipolar Depression. The Journal of ECT, 28, e39-e40. https://doi.org/10.1097/yct.0b013e318255a552
[12]
Salloum, N.C., Fava, M., Hock, R.S., Freeman, M.P., Flynn, M., Hoeppner, B., et al. (2020) Time to Relapse after a Single Administration of Intravenous Ketamine Augmentation in Unipolar Treatment-Resistant Depression. Journal of Affective Disorders, 260, 131-139. https://doi.org/10.1016/j.jad.2019.09.017
